• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Daily Dose: Lung Cancer Screening Significantly Increases Long-Term Survival Rate

Daily Dose: Lung Cancer Screening Significantly Increases Long-Term Survival Rate / Image Credit: ©New Africa/AdobeStock
©New Africa/AdobeStock

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

Last week, we reported on findings from a study published in the journal Radiology.

The study

Researchers conducted the study to determine the 20-year lung cancer-specific survival of persons diagnosed with first primary lung cancer through annual low-dose CT screening in the expanded International ELCAP (I-ELCAP) multicenter, global research program. In the I-ELCAP program, a total of 89 404 patients underwent lung cancer screening between 1992 and 2022.


Results demonstrated a 10-year lung cancer–specific survival rate of 81% (95% CI, 79%-84%) and a 20-year lung cancer–specific survival rate of 81% (95% CI, 78%-83%) in patients who were diagnosed with lung cancer through early CT screening. Among patients who were diagnosed with stage I disease (≤10mm), the survival rate was 95% (95% CI, 91%-98%).

Authors' comment

"The 20-year follow-up provides an estimate of the cure rate achieved in annual screening programs using a well-defined protocol and comprehensive management system, which allows for identification of early lung cancer while it is still small and curable."

Click here for more details.

© 2024 MJH Life Sciences

All rights reserved.